

# UHL Research and Innovation: Quarterly Trust Board Report April 2016

Trust Board paper N

Author: Nigel Brunskill, Director of Research and Innovation Sponsor: Andrew Furlong, Medical Director

## Executive Summary

### Context

UHL is a Trust active in Research and Innovation (R&I). This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

### Questions

1. Is UHL performing well in the delivery of quality research at expected volume?
2. Are large projects planned with appropriate partners and managed appropriately?
3. Are upcoming challenges understood?

### Conclusion

1. UHL performs well in delivering high quality research as judged by NIHR and LCRN data.
2. A larger number of large projects are in development, some being close to start date. There is a wide range of NHS and Academic partner engagement.
3. A number of challenges are recognised and planning is in place to mitigate risks.

### Input Sought

Report is presented for information.

The Trust Board's attention is particularly drawn to: the importance of the upcoming BRC application; the decision about future use of Life Study Centre; the need to deliver cancer recruitment into 100,000 Genome Project; and the pressures around capacity for clinical trials in Cancer Studies.

# For Reference

Edit as appropriate:

1. The following [objectives](#) were considered when preparing this report:

Safe, high quality, patient centred healthcare	[Yes]
Effective, integrated emergency care	[Yes]
Consistently meeting national access standards	[Not applicable]
Integrated care in partnership with others	[Yes]
Enhanced delivery in research, innovation & ed'	[Yes]
A caring, professional, engaged workforce	[Yes]
Clinically sustainable services with excellent facilities	[Yes]
Financially sustainable NHS organisation	[Yes]
Enabled by excellent IM&T	[Yes]

2. This matter relates to the following [governance](#) initiatives:

Organisational Risk Register	[Yes]
Board Assurance Framework	[Yes]

3. Related [Patient and Public Involvement](#) actions taken, or to be taken: [Insert here]

4. Results of any [Equality Impact Assessment](#), relating to this matter: n/a

5. Scheduled date for the [next paper](#) on this topic: [TBC]

6. Executive Summaries should not exceed [1page](#). [My paper does / does not comply]

7. Papers should not exceed [7 pages](#). [My paper does comply]

# UHL R&I Quarterly Trust Board Report April 2016

## 1. Introduction

This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

## 2. Research Performance

The activity of UHL in initiating and delivering clinical research is performance monitored by both the NIHR Central Commissioning Facility (NIHR CCF) and the East Midlands Clinical Research Network (EM CRN). In turn the UHL R&I Office reports research CMG level activity and performance to each CMG via the R&I Executive Committee.

### 2.1 NIHR CCF.

In Q3 15/16 UHL initiated 116 clinical trials. These figures confirm a continuing increase over the year.

**Table 1: UHL Performance in initiating clinical research trials**

	Number of Trials Initiated		
	2013/14	2014/15	2015/16
Q1	111	91	107
Q2	125	79	107
Q3	121	82	116
Q4	116	95	

UHL is also judged by its performance in recruiting patients into initiated trials within 70 days. In Q3 2015/16 this figure was >70% and represents a sustained improvement over the position 12 months ago.

Overall in terms of both initiating and delivering research UHL is ranked in League 1 (of 7) by NIHR.

### 2.2. EM CRN.

Recruitment into clinical trials up to end Jan 2016 stands at 10,923 individuals. This exceeds recruitment for the similar period in 14/15 when UHL significantly exceeded targets (Table 2). UHL is the highest recruiting trust in the East Midlands.

**Table 2: Cumulative Recruitment Numbers of Patients into UHL Studies 2014/15 and 15/16**

	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
Cumulative Recruitment 14/15	950	2047	3007	4079	5314	6224	7282	8363	9169	10223	11266	12564
Cumulative Recruitment 15/16	1078	1946	3112	4112	4972	5961	7477	9327	10112	10923		

### **3. Projects in Development**

#### **3.1 New Projects under Development.**

##### ***3.1.1 NIHR Biomedical Research Centres (BRCs)***

A PQQ has been completed in application for a BRC led by UHL with University of Leicester and Loughborough University as academic partners. There will be three themes: cardiovascular, respiratory, and diet and lifestyle. Precision medicine will be a cross-cutting theme.

##### ***3.1.2 NHIR Renew and Refresh Call for Clinical Research Facility (CRF) Funding***

UHL will lead an application for funding from NIHR to meet the necessary recurrent NHS infrastructure costs and NHS support costs of funded, world-class, early translational research undertaken in existing CRF facilities at UHL. The application will be circa £1.5 million and will be made alongside and complementary to the BRC application.

#### **3.2. Existing Projects.**

##### ***3.2.1. The 100,000 Genome Project.***

UHL is now delivering recruitment to the rare diseases component of this project to an agreed trajectory. The next challenge is to begin recruitment to the cancer component of this project.

##### ***3.2.2. UHL-University of Leicester Joint Research Office***

With our UoL partners we will develop closer joint research office working by bringing finance and enterprise into our joint activities.

### **4. Innovation/Enterprise Activities**

- SPACE- COPD (Pulmonary Rehabilitation)- Manuals, Licences sold to trusts and Pharma companies - significant financial benefit to the Trust
- Bifurcated Stent – remains in development with high possibility of gaining external funds to set up a Spin-Out company
- UHL will be attending Medi Tech Expo, Coventry, April 2016.
- UHL has signed an agreement to be a preferred partner for clinical trials with Parexel International
- UHL patients recruited to 100,000 genome project featured in national print media and national TV

### **5. New/Existing Challenges**

#### ***5.1. Delivery of 100,000 Genome Project***

This is a high profile project but requires service transformation for future mainstreaming into clinical practice. Discussions held with relevant colleagues from W&C CMG.

#### ***5.2. Clinical Research Network Budget for 2016/17***

An infrastructure budget has been submitted to CRN for approval. There is some pressure around clinical trials pharmacy and we are working with network colleagues to identify a solution.

#### ***5.3 Hope Unit at Glenfield***

There is lack of capacity for clinical trials in cancer studies. Efforts continue to identify suitable space for Hope Unit at Glenfield Hospital

#### ***5.4 Life Study Centre***

After discussions with colleagues in Estates and Facilities it has been agreed that Life Study Centre be retained as a clinical research facility for general use renamed as LGH Clinical Research Centre. Agreed criteria will determine prioritisation of research activity for allocation of space with cancer studies and W&C related research given highest priority.

Nigel Brunskill  
March 2016